The price of Wave Life Sciences Ltd. (NASDAQ:WVE) shares last traded on Wall Street rose 2.51% to $4.09.
Based on available information, 7 analysts follow Wave Life Sciences Ltd. (NASDAQ:WVE). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $17.00 and a low of $3.00, we find $7.00. Given the previous closing price of $3.99, this indicates a potential upside of 75.44 percent. WVE stock price is now -13.29% away from the 50-day moving average and 3.97% away from the 200-day moving average. The market capitalization of the company currently stands at $378.12M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Among analysts, 3 rate the stock a hold while 4 rate it a buy. Brokers who have rated the stock have averaged $8.57 as their price target over the next twelve months.
On October 23, 2020, RBC Capital Mkts recently initiated its ‘Sector Perform’ rating on the stock quoting a target price of $13, while ‘SVB Leerink’ rates the stock as ‘Mkt Perform’.
In other news, BOLNO PAUL, President and CEO sold 29,400 shares of the company’s stock on Feb 16. The stock was sold for $118,776 at an average price of $4.04. Upon completion of the transaction, the President and CEO now directly owns 407,425 shares in the company, valued at $1.67 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 16, See Remarks Francis Chris sold 10,258 shares of the business’s stock. A total of $41,340 was realized by selling the stock at an average price of $4.03. This leaves the insider owning 79,714 shares of the company worth $0.33 million. Insiders disposed of 142,453 shares of company stock worth roughly $0.58 million over the past 1 year. A total of 28.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in WVE stock. A new stake in Wave Life Sciences Ltd. shares was purchased by DAVIDSON KEMPNER CAPITAL MANAGEMENT LP during the first quarter worth $3,967,000. MARSHALL WACE, LLP invested $1,339,000 in shares of WVE during the first quarter. In the first quarter, WELLINGTON MANAGEMENT GROUP LLP acquired a new stake in Wave Life Sciences Ltd. valued at approximately $986,000. CASDIN CAPITAL, LLC acquired a new stake in WVE for approximately $818,000. JANE STREET GROUP, LLC purchased a new stake in WVE valued at around $425,000 in the second quarter. In total, there are 93 active investors with 78.70% ownership of the company’s stock.
A candlestick chart of Wave Life Sciences Ltd. (NASDAQ: WVE) showed a price of $3.9400 on Thursday morning. During the past 12 months, Wave Life Sciences Ltd. has had a low of $1.16 and a high of $7.12. The fifty day moving average price for WVE is $4.7172 and a two-hundred day moving average price translates $3.9341 for the stock.
The latest earnings results from Wave Life Sciences Ltd. (NASDAQ: WVE) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.42, beating analysts’ expectations of -$0.5 by 0.08. This compares to -$0.12 EPS in the same period last year. The company reported revenue of $0.28 million for the quarter, compared to $36.42 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -99.22 percent. For the current quarter, analysts expect WVE to generate $7.06M in revenue.
Wave Life Sciences Ltd.(WVE) Company Profile
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington’s disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Leave a Reply